Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Madrigal Pharmaceuticals, Inc. (MDGL)

Caris Life Sciences,�Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Madrigal Pharmaceuticals, Inc. are of similar size ($9.9B and $9.7B). Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 86.1×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 96.4%. Caris Life Sciences,�Inc. has the higher net margin (10.6% vs −25.3%) and the higher return on invested capital (50.0% vs −787.3%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 14 and Madrigal Pharmaceuticals, Inc. on 3.

Valuation

Metric CAI MDGL Biotechnology median
P/E 86.06 n/m 10.71
P/S 9.25 9.84 9.84
P/B 15.47 24.12 2.15
Price to free cash flow 73.83 n/m 25.78
EV/EBITDA 48.62 n/m 0.65
EV/Sales 8.84 9.45 9.47
Earnings yield 1.16% (2.97%) (34.53%)
Free cash flow yield 1.35% (1.66%) (24.00%)

Profitability

Metric CAI MDGL Biotechnology median
Gross margin 69.66% 91.48% 69.20%
Operating margin 15.49% (25.13%) 0.00%
Net margin 10.62% (25.32%) 0.00%
Free cash flow margin 12.53% (16.07%) 0.00%
Return on equity 20.13% (53.31%) (53.10%)
Return on assets 9.62% (28.77%) (46.06%)
Return on invested capital 49.95% (787.33%) 0.00%

Growth

Metric CAI MDGL Biotechnology median
Revenue growth (TTM) 96.36% 149.04% 5.26%
EPS growth (last fiscal year) 69.79% 41.32% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI MDGL Biotechnology median
Debt to equity 0.66 0.65 0.00
Current ratio 5.53 3.20 4.98
Net debt to EBITDA (5.23) 2.21 1.01

Dividend

Metric CAI MDGL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CAI MDGL Biotechnology median
Market cap 9.70b 9.94b 171.46m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack